Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.52 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL695617 | 0.90 | MAP2K1 (0.53) | MAP2K1MAP2K2LDHA | |
| SCHEMBL696463 | 0.90 | MAP2K1 (0.59) | MAP2K1MAP2K2 | |
| SCHEMBL696292 | 0.89 | MAP2K1 (0.56) | MAP2K1MAP2K2MAPK14HPGDLDHA | |
| SCHEMBL696870 | 0.88 | MAP2K1 (0.57) | MAP2K1MAP2K2ALDH1A1 | |
| SCHEMBL696857 | 0.86 | MAP2K1 (0.55) | MAP2K1MAP2K2ALDH1A1LDHA | |
| SCHEMBL698475 | 0.85 | MAP2K1 (0.55) | MAP2K1MAP2K2 | |
| SCHEMBL696176 | 0.83 | MAP2K1 (0.51) | MAP2K1MAP2K2ALDH1A1 | |
| SCHEMBL13148371 | 0.83 | MAP2K1 (0.52) | MAP2K1MAP2K2ALDH1A1 | |
| SCHEMBL694662 | 0.83 | MAP2K1 (0.60) | MAP2K1MAP2K2ALDH1A1 | |
| SCHEMBL694901 | 0.82 | MAP2K1 (0.65) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421612-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | Novartis AG (CH) | 2012-02-29 | — | — | EP | claimed |
| EP-2421612-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | Novartis AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NRAS, BRAF, MAP3K1 | MAP2K1 48/4885MAP2K2 38/4885CYP1A2 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.